Sal has been shown to overcome apoptosis-resistance in several types of cancer cells with far less side effects, and inhibits tumor metastasis and recurrence by disruption TGF-β1-induced epithelial-to-mesenchymal transition (EMT) and/or other signaling pathways [50, 51], which might help to prevent and/or delay treatment resistance in anti-angiogenic therapy. This evidence concerns the gene TGFB1 and cancer.